Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1995 Apr;100(1):32–39. doi: 10.1111/j.1365-2249.1995.tb03600.x

Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine.

A E Platonov 1, V B Beloborodov 1, L I Pavlova 1, I V Vershinina 1, H Käyhty 1
PMCID: PMC1534267  PMID: 7697919

Abstract

Eighteen patients with late complement component deficiency (LCCD) were immunized with meningococcal capsular polysaccharide vaccine. The LCCD patients had experienced one-to-five meningococcal infections before vaccination, but their immunological and clinical status was normal at the time of immunization. Serum samples from vaccinated complement-sufficient relatives of the LCCD patients and healthy Russian male adults were used as controls. Total and immunoglobulin-specific concentrations of antibodies to group A, C, W135, and Y capsular polysaccharides were determined by enzyme immunoassay in serum samples taken before and 1-108 weeks after immunization. The individual preimmunization and post-immunization antibody concentrations varied greatly. The median antibody concentrations of the LCCD patients increased significantly after vaccination, and were not significantly different from those of the control groups. The antibody concentrations remained elevated for at least 1 year after vaccination. The post-immunization antibody concentrations correlated with the number of meningococcal infections within 10 years before vaccination. In spite of the vaccination two LCCD patients experienced a meningococcal disease 9 and 12 months, respectively, after vaccination.

Full text

PDF
32

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambrosch F., Wiedermann G., Crooy P., George A. M. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull World Health Organ. 1983;61(2):317–323. [PMC free article] [PubMed] [Google Scholar]
  2. Andreoni J., Käyhty H., Densen P. Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J Infect Dis. 1993 Jul;168(1):227–231. doi: 10.1093/infdis/168.1.227. [DOI] [PubMed] [Google Scholar]
  3. Arakere G., Frasch C. E. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect Immun. 1991 Dec;59(12):4349–4356. doi: 10.1128/iai.59.12.4349-4356.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Biselli R., Casapollo I., D'Amelio R., Salvato S., Matricardi P. M., Brai M. Antibody response to meningococcal polysaccharides A and C in patients with complement defects. Scand J Immunol. 1993 Jun;37(6):644–650. doi: 10.1111/j.1365-3083.1993.tb01677.x. [DOI] [PubMed] [Google Scholar]
  5. Bjune G., Høiby E. A., Grønnesby J. K., Arnesen O., Fredriksen J. H., Halstensen A., Holten E., Lindbak A. K., Nøkleby H., Rosenqvist E. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet. 1991 Nov 2;338(8775):1093–1096. doi: 10.1016/0140-6736(91)91961-s. [DOI] [PubMed] [Google Scholar]
  6. Carlone G. M., Frasch C. E., Siber G. R., Quataert S., Gheesling L. L., Turner S. H., Plikaytis B. D., Helsel L. O., DeWitt W. E., Bibb W. F. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol. 1992 Jan;30(1):154–159. doi: 10.1128/jcm.30.1.154-159.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Costantino P., Viti S., Podda A., Velmonte M. A., Nencioni L., Rappuoli R. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine. 1992;10(10):691–698. doi: 10.1016/0264-410x(92)90091-w. [DOI] [PubMed] [Google Scholar]
  8. Figueroa J. E., Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991 Jul;4(3):359–395. doi: 10.1128/cmr.4.3.359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gotschlich E. C., Rey M., Triau R., Sparks K. J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest. 1972 Jan;51(1):89–96. doi: 10.1172/JCI106801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hankins W. A., Gwaltney J. M., Jr, Hendley J. O., Farquhar J. D., Samuelson J. S. Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C, Y, and W135. Proc Soc Exp Biol Med. 1982 Jan;169(1):54–57. doi: 10.3181/00379727-169-41306. [DOI] [PubMed] [Google Scholar]
  11. Jarvis G. A., Griffiss J. M. Human IgA1 blockade of IgG-initiated lysis of Neisseria meningitidis is a function of antigen-binding fragment binding to the polysaccharide capsule. J Immunol. 1991 Sep 15;147(6):1962–1967. [PubMed] [Google Scholar]
  12. Käyhty H., Jousimies-Somer H., Peltola H., Mäketä P. H. Antibody response to capsular polysaccharides of groups A and C neisseria meningitidis and Haemophilus influenzae type b during bacteremic disease. J Infect Dis. 1981 Jan;143(1):32–41. doi: 10.1093/infdis/143.1.32. [DOI] [PubMed] [Google Scholar]
  13. Le Moli S., Matricardi P. M., Quinti I., Stroffolini T., D'Amelio R. Clonotypic analysis of human antibodies specific for Neisseria meningitidis polysaccharides A and C in adults. Clin Exp Immunol. 1991 Mar;83(3):460–465. doi: 10.1111/j.1365-2249.1991.tb05661.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Mannion B. A., Weiss J., Elsbach P. Separation of sublethal and lethal effects of polymorphonuclear leukocytes on Escherichia coli. J Clin Invest. 1990 Aug;86(2):631–641. doi: 10.1172/JCI114755. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Morgan B. P. Effects of the membrane attack complex of complement on nucleated cells. Curr Top Microbiol Immunol. 1992;178:115–140. doi: 10.1007/978-3-642-77014-2_8. [DOI] [PubMed] [Google Scholar]
  16. Mäkelä P. H., Peltola H., Käyhty H., Jousimies H., Pettay O., Ruoslahti E., Sivonen A., Renkonen O. V. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis. 1977 Aug;136 (Suppl):S43–S50. doi: 10.1093/infdis/136.supplement.s43. [DOI] [PubMed] [Google Scholar]
  17. O'Reilly R. J., Anderson P., Ingram D. L., Peter G., Smith D. H. Circulating polyribophosphate in Hemophilus influenzae, type b meningitis. Correlation with clinical course and antibody response. J Clin Invest. 1975 Oct;56(4):1012–1022. doi: 10.1172/JCI108148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Orren A., Warren R. E., Potter P. C., Jones A. M., Lachmann P. J., Poolman J. T. Antibodies to meningococcal class 1 outer membrane proteins in South African complement-deficient and complement-sufficient subjects. Infect Immun. 1992 Nov;60(11):4510–4516. doi: 10.1128/iai.60.11.4510-4516.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Phipps D. C., West J., Eby R., Koster M., Madore D. V., Quataert S. A. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods. 1990 Dec 31;135(1-2):121–128. doi: 10.1016/0022-1759(90)90264-v. [DOI] [PubMed] [Google Scholar]
  20. Platonov A. E., Beloborodov V. B., Gabrilovitch D. I., Khabarova V. V., Serebrovskaya L. V. Immunological evaluation of late complement component-deficient individuals. Clin Immunol Immunopathol. 1992 Aug;64(2):98–105. doi: 10.1016/0090-1229(92)90186-r. [DOI] [PubMed] [Google Scholar]
  21. Platonov A. E., Beloborodov V. B., Vershinina I. V. Meningococcal disease in patients with late complement component deficiency: studies in the U.S.S.R. Medicine (Baltimore) 1993 Nov;72(6):374–392. doi: 10.1097/00005792-199311000-00002. [DOI] [PubMed] [Google Scholar]
  22. Potter P. C., Frasch C. E., van der Sande W. J., Cooper R. C., Patel Y., Orren A. Prophylaxis against Neisseria meningitidis infections and antibody responses in patients with deficiency of the sixth component of complement. J Infect Dis. 1990 May;161(5):932–937. doi: 10.1093/infdis/161.5.932. [DOI] [PubMed] [Google Scholar]
  23. Schlesinger M., Greenberg R., Levy J., Kayhty H., Levy R. Killing of meningococci by neutrophils: effect of vaccination on patients with complement deficiency. J Infect Dis. 1994 Aug;170(2):449–453. doi: 10.1093/infdis/170.2.449. [DOI] [PubMed] [Google Scholar]
  24. Sjöholm A. G. Inherited complement deficiency states: implications for immunity and immunological disease. APMIS. 1990 Oct;98(10):861–874. doi: 10.1111/j.1699-0463.1990.tb05008.x. [DOI] [PubMed] [Google Scholar]
  25. de Moraes J. C., Perkins B. A., Camargo M. C., Hidalgo N. T., Barbosa H. A., Sacchi C. T., Landgraf I. M., Gattas V. L., Vasconcelos H. de G., Gral I. M. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet. 1992 Oct 31;340(8827):1074–1078. doi: 10.1016/0140-6736(92)93086-3. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES